What You Need to Know
After discussions with the FDA, Takeda issued a US recall on September 5, 2019, for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg).
NATPARA is a parathyroid hormone currently approved in the US as the only adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone (calcium and vitamin D).
With patient safety as the company's main priority, Takeda is communicating directly with US healthcare professionals, who have already received this information, as well as with patients and specialty pharmacies. Discontinuing NATPARA abruptly can cause a sharp decrease in blood calcium levels (severe hypocalcemia) which can result in serious health consequences. It is critically important that patients contact their prescribing healthcare provider to discuss their individual treatment plan and ensure close supervision, including frequent monitoring of blood calcium levels and close titration of active vitamin D and calcium supplements upon stopping NATPARA to avoid low blood calcium (hypocalcemia).
All of us at Takeda understand the impact that this recall has on patients, and we are continuing to work closely with the FDA until we are able to resolve the issue. Takeda values the US FDA’s collaboration and feedback as we work together to resupply NATPARA to patients who need it.
If you have questions or concerns about this recall, browse the information on this page, and talk with your doctor. For more details, read our PDF. Be sure to bookmark this page and check back often for the latest updates.
Letter to Patients
Updated FDA Classification
Letter to Patients
Special Use Program
Recall Press Release
NATPARA Special Use Program
If you are a patient previously prescribed NATPARA who is facing life-threatening complications as a result of discontinuation of NATPARA, despite efforts to actively manage your condition, your healthcare provider will be able to request NATPARA for you. The Medical Review committee will then evaluate eligibility on a case-by-case basis.Get Details
OnePath® is Here to Help
Our experienced Patient Support Managers can work with you one-on-one to answer your questions at 1-866-888-0660, Monday through Friday 8:30 a.m. to 8:00 p.m. ET.View Program